Why health-care costs are rising in the U.S. more than anywhere else

Health, Fitness & Food

Health-care spending is rising around the world, but the U.S. is the worst performer. The United States accounts for more than 40% of all global health spending.

Health-care spending made up 5% of total U.S. GDP in 1960. In 2020, spending hit almost 20% of total U.S. GDP.

“Health care almost always outpaces inflation, and so health-care costs grow faster than the economy,” said Cynthia Cox, vice president at the Kaiser Family Foundation. “That’s why it’s representing a larger and larger share of the economy.”

Americans aren’t using more health care than people in other nations that spend less. Instead, U.S. residents pay more for each interaction. Hospitals, physicians and clinical care made up more than half of the total health-care spending in 2019.

One of the causes of high spending is the fragmented nature of the U.S. system. Some Americans have comprehensive and affordable health insurance coverage while others have little to no coverage.

“The way the system is structured now, it is a cure-driven system, not a prevention-driven system,” said Yaseen Hayajneh, associate professor of health administration at Western Connecticut State University.

“Preventing diseases from getting worse is always going to cost less,” said Dr. Tyeese Gaines, an emergency medicine physician who also previously ran her own practice.

Most Americans don’t have much of a choice when it comes to their insurance plan. More than 54% get health insurance through their employer. This lack of choice limits competition, which can drive prices higher.

“[The] capitalist view works when the market is free,” Hayajneh told CNBC. “Health care is never a free market.”

Watch the video above to learn more about why health-care costs are rising in the U.S. more than anywhere else and how that can be stopped.

Products You May Like

Articles You May Like

Running Is Inherently Political — and It’s About Time TikTok Has the Conversation
Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs
UnitedHealth’s rough stretch continues, with buyouts, a reported DOJ probe and a 23% drop in three months
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
What Cramer wants to hear from Nvidia, Salesforce — plus, Lilly does what no other can

Leave a Reply

Your email address will not be published. Required fields are marked *